Quanterix Corp
NASDAQ:QTRX

Watchlist Manager
Quanterix Corp Logo
Quanterix Corp
NASDAQ:QTRX
Watchlist
Price: 10.52 USD -1.22% Market Closed
Market Cap: 403.8m USD
Have any thoughts about
Quanterix Corp?
Write Note

Quanterix Corp
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Quanterix Corp
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Quanterix Corp
NASDAQ:QTRX
Other Current Liabilities
$10.1m
CAGR 3-Years
9%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Other Current Liabilities
$2.7B
CAGR 3-Years
23%
CAGR 5-Years
23%
CAGR 10-Years
15%
Danaher Corp
NYSE:DHR
Other Current Liabilities
$1.6B
CAGR 3-Years
-4%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Other Current Liabilities
$431.7m
CAGR 3-Years
10%
CAGR 5-Years
15%
CAGR 10-Years
11%
Agilent Technologies Inc
NYSE:A
Other Current Liabilities
$544m
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
-5%
IQVIA Holdings Inc
NYSE:IQV
Other Current Liabilities
$2.3B
CAGR 3-Years
4%
CAGR 5-Years
16%
CAGR 10-Years
15%
No Stocks Found

Quanterix Corp
Glance View

Market Cap
403.9m USD
Industry
Life Sciences Tools & Services

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.

QTRX Intrinsic Value
16.45 USD
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Quanterix Corp's Other Current Liabilities?
Other Current Liabilities
10.1m USD

Based on the financial report for Jun 30, 2024, Quanterix Corp's Other Current Liabilities amounts to 10.1m USD.

What is Quanterix Corp's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
14%

Over the last year, the Other Current Liabilities growth was -3%. The average annual Other Current Liabilities growth rates for Quanterix Corp have been 9% over the past three years , 14% over the past five years .

Back to Top